Nedvídková J, Vavrejnová V, Pacák K, Vichtrle D, Nĕmec J, Bednár J
Výzkumný ústav endokrinologický, Praha.
Cas Lek Cesk. 1990 Nov 2;129(44):1384-8.
Beta-adrenergic receptors and production of cyclic adenosine monophosphate (cAMP) was investigated in peripheral lymphocytes of patients with differentiated thyroid carcinoma in hypothyroidism and euthyroidism, following therapy with 131I and suppression with thyroid hormones. After 131I therapy of patients with differentiated thyroid carcinoma and suppression by means of thyroid hormones, when the patients became euthyroid, the authors found a significantly lower maximal binding capacity Bmax on lymphocytes, as compared with the same patients before radiotherapy when the patients were hypothyroid. The basic cAMP content in patients with euthyroidism was higher, as compared with hypothyroid patients, the difference being at the borderline of significance (p less than 0.06). In vitro stimulation of cAMP formation by lymphocytes using the beta-adrenergic agonist isoprenaline was similar in hypo- and euthyroid patients and did not change in the course of treatment. When expressed in per cent, the stimulation of cAMP formation during euthyroidism was rather lower. Stimulation of cAMP formation by forskoline, an activator of adenylate cyclase was significantly higher in euthyroidism. Simultaneous addition of isoprenaline and forskoline to the incubation medium with lymphocytes produced an additive effect with markedly higher stimulation in euthyroidism. The reduced maximum binding capacity for 3H-dihydroalprenolol (3H-DHA) in euthyroid patients is discussed with regard to the probable influence of the basic disease, participation of radiation and the possible influencing of the immune system on changes in the number and activity of the patients' receptor system.
在甲状腺功能减退和甲状腺功能正常的分化型甲状腺癌患者接受¹³¹I治疗及甲状腺激素抑制治疗后,对其外周淋巴细胞中的β-肾上腺素能受体及环磷酸腺苷(cAMP)的产生情况进行了研究。在分化型甲状腺癌患者接受¹³¹I治疗并采用甲状腺激素抑制治疗后,当患者甲状腺功能恢复正常时,作者发现与放疗前甲状腺功能减退时相比,淋巴细胞上的最大结合能力Bmax显著降低。与甲状腺功能减退患者相比,甲状腺功能正常患者的基础cAMP含量更高,差异接近显著水平(p小于0.06)。在体外,使用β-肾上腺素能激动剂异丙肾上腺素刺激淋巴细胞生成cAMP的情况在甲状腺功能减退和甲状腺功能正常的患者中相似,且在治疗过程中没有变化。以百分比表示时,甲状腺功能正常时cAMP生成的刺激程度相对较低。在甲状腺功能正常时,由腺苷酸环化酶激活剂福斯高林刺激cAMP生成的作用显著更高。在含有淋巴细胞的孵育培养基中同时添加异丙肾上腺素和福斯高林会产生相加效应,在甲状腺功能正常时刺激作用明显更高。关于基础疾病的可能影响、辐射的参与以及免疫系统可能对患者受体系统数量和活性变化的影响,讨论了甲状腺功能正常患者中³H-二氢阿普洛尔(³H-DHA)最大结合能力降低的情况。